AstraZeneca PLC (AZN)vsSyndax Pharmaceuticals Inc (SNDX)
AZN
AstraZeneca PLC
$158.50
-0.81%
HEALTHCARE · Cap: $263.09B
SNDX
Syndax Pharmaceuticals Inc
$19.80
-2.41%
HEALTHCARE · Cap: $1.69B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 28157% more annual revenue ($61.37B vs $217.17M). AZN leads profitability with a 17.0% profit margin vs -112.0%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
SNDX
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+19.3%
Fair Value
$196.68
Current Price
$158.50
$38.18 discount
Intrinsic value data unavailable for SNDX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Revenue surging 223.6% year-over-year
Areas to Watch
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Trading at 42.1x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.47 suggests the stock is reasonably priced for its growth.
Bull Case : SNDX
The strongest argument for SNDX centers on Revenue Growth. Revenue growth of 223.6% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Bear Case : SNDX
The primary concerns for SNDX are EPS Growth, Market Cap, Piotroski F-Score. Debt-to-equity of 39.03 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while SNDX is a hypergrowth play — different risk/reward profiles.
SNDX carries more volatility with a beta of 0.37 — expect wider price swings.
SNDX is growing revenue faster at 223.6% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 31/100), backed by strong 17.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Syndax Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company is headquartered in Waltham, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?